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Introduction
Interstitial lung disease (ILD) frequently coexists with col-
lagen vascular disease (CVD) in patients, and most such 
patients are treated with immunosuppressive agents. Lung 
cancer in patients with ILD has a poor prognosis, and the 
postoperative acute exacerbation (AE) of ILD is one of the 
most critical complications observed after lung resection. 
Recently, Fukui et  al. report that patients with combined 
pulmonary fibrosis and emphysema show poor postopera-
tive outcomes after lung cancer surgery [1]. Although the 
prognosis of CVD-associated ILD (CVD-ILD) is better 
than that of idiopathic interstitial pneumonias (IIPs) [2], 
the effect of CVD-ILD on the prognosis of lung cancer 
compared to that of IIPs and the incidence of postopera-
tive AE of CVD-ILD are unknown. In addition, the use of 
immunosuppressive agents may increase the risk of postop-
erative complications, such as bronchopleural fistula (BPF). 
Consequently, CVD-ILD patients undergoing lung cancer 
surgery are speculated to have a higher risk of postopera-
tive morbidities and mortality. However, to date, there is 
no report regarding the outcomes of lung cancer surgery 
in CVD-ILD patients. This study compared the effect of 
CVD-ILD with that of patients with IIPs on the outcomes 
of lung cancer surgery.
Patients and methods
This was a single-institutional retrospective study based 
on medical records obtained from the authors’ institution. 
Abstract 
Purpose This study compared the effect of collagen vas-
cular disease-associated interstitial lung disease (CVD-
ILD) with that of idiopathic interstitial pneumonias (IIPs) 
on the outcomes of lung cancer surgery.
Methods This study retrospectively reviewed the medi-
cal records of patients who underwent surgery for non-
small cell lung cancer (NSCLC) and compared the data of 
16 patients with CVD-ILD with those of 70 patients with 
IIPs. The patterns of interstitial lung disease (ILD) on chest 
computed tomography were classified into usual interstitial 
pneumonia (UIP) and non-specific interstitial pneumonia 
(NSIP) patterns.
Results The numbers of UIP and NSIP patterns were 10 
(62.5%) and 6 (37.5%) patients in CVD-ILD group, and 62 
(88.6%) and 8 (11.4%) patients in IIPs group, respectively. 
A postoperative acute exacerbation (AE) appeared in 1 
patient (6.3%) in the CVD-ILD group and 6 patients (8.6%) 
in the IIPs group. No significant differences in the inci-
dence of postoperative AE and mortalities were observed 
between the two groups. The five-year overall survival rates 
of the CVD-ILD and IIPs groups were 37.5 and 49.2%, 
respectively.
Conclusions Surgery for NSCLC in CVD-ILD patients 
appear to cause no increase in postoperative AE and mor-
tality in comparison to that seen in IIPs patients. Similar 
to IIPs, CVD-ILD might therefore affect the prognosis of 
resected NSCLC.
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The authors reviewed the clinical data of 1114 patients who 
underwent lung resection for non-small cell lung cancer 
(NSCLC) at our institution from January 2003 to Decem-
ber 2014. These patients were classified into two groups, 
including patients with CVD (n = 40) and those without 
(n = 1074). Then, based on the chest computed tomogra-
phy (CT) findings described below, the patients belong-
ing to the CVD-ILD group (n = 16) and those belonging to 
the IIPs group (n = 70) were newly extracted from the two 
groups individually (Fig.  1). The postoperative follow-up 
period was defined as the period from operation to the last 
follow-up appointment.
Diagnosis of interstitial lung disease
The diagnosis of ILD was based on the following criteria, 
and the patterns of ILD on chest CT was classified into 
usual interstitial pneumonia (UIP) and non-specific inter-
stitial pneumonia (NSIP) patterns. The criteria for the UIP 
pattern were (1) subpleural basal predominance, (2) retic-
ular abnormality, (3) honeycombing with or without trac-
tion bronchiectasis, and (4) the absence of features listed 
as inconsistent with UIP pattern as described in the litera-
ture [3]. Any patients with a possible UIP pattern on CT 
[3] were excluded from this study. The criteria for the NSIP 
pattern were reticular opacities with a lower lung zone pre-
dominance, associated with traction bronchiectasis, and 
lobar volume loss [4]. CT scanned images were read by 
both experienced radiologists and thoracic surgeons. After 
surgery, all resected specimens were investigated by pathol-
ogists to confirm the existence of ILD.
Prophylaxis for an acute exacerbation of interstitial 
pneumonia
At the authors’ institution, ulinastatin, as a prophylactic 
treatment for postoperative AE after pulmonary resection, 
was used for patients with simultaneous lung cancer and 
ILD [5]. Two days before surgery, ulinastatin was admin-
istered as a 30-min infusion of 300,000 units (U) for three 
consecutive days. The dose of ulinastatin for days 4 to 6 
was reduced to 200,000 U, and that for days 7 –9 was fur-
ther reduced to 100,000 U.
Definition of postoperative event
Postoperative complications were defined as complications 
that appeared within 30 days after surgery and included (1) 
arrhythmia requiring intervention, and (2) prolonged air 
leakage persisting for 7 days postoperatively and requir-
ing pleurodesis. In addition, the 30- and 90-day mortali-
ties were defined as death within 30 and 90 days after sur-
gery, respectively, and included any instances of death after 
discharge.
Postoperative AE was diagnosed according to the fol-
lowing diagnostic criteria: (1) an unexplained worsening 
or the development of dyspnea within 30 days, (2) a new 
bilateral ground-glass abnormality and/or consolidation 
superimposed on a background reticular or honeycomb pat-
tern on CT scan, (3) worsening hypoxemia from a known 
baseline arterial blood gas level, (4) the absence of infec-
tious disease, (5) the exclusion of alternative causes includ-
ing left heart failure and pulmonary embolism and (6) the 
identifiable cause of acute lung injury [3, 6]. Patients with 
postoperative AE received steroid pulse therapy with meth-
ylprednisolone as the first line treatment.
Statistical analysis
Categorical data were presented as numbers and percent-
ages, and continuous data were presented as the median 
and interquartile range (IQR). For comparing CVD-ILD 
and IIPs groups, the categorical data were analyzed by the 
Fisher’s exact test or the Chi-square test, and continuous 
data were analyzed by the Mann–Whitney U test. Overall 
survival (OS) was defined as the time from the operation 
to death from any cause, and the 5-year OS rate was esti-
mated by the Kaplan–Meier method. Differences between 
the two groups were analyzed by the log-rank test. Prob-
abilities of less than 0.05 (p < 0.05) were considered statis-
tically significant. All statistical analyses were performed 
by JMP Pro 12.1 statistical software (SAS Institute, Cary, 
NC, USA).
Ethics
This study was approved by the Research Ethics Com-
mittee of the Tokyo Women’s Medical University, Tokyo, 
Japan (No.3852).
Fig. 1  Study enrolment flow chart. CT indicates computed tomog-
raphy; CVD, collagen vascular disease; CVD-ILD,collagen vascular 
disease associated interstitial lung disease; IIPs, idiopathic interstitial 




Sixteen patients with CVD-ILD underwent lung resection 
for NSCLC at the authors’ institution during the study 
period and their baseline characteristics are given in 
Table 1. The median age was 66.5 years (IQR: 16 years), 
6 patients (37.5%) were men, and 10 patients (62.5%) 
were women. There were significant differences in gen-
der (p = 0.0201) and the Brinkman index (p = 0.0057) 
between the CVD-ILD and IIPs groups. ILD patterns on 
chest CT in CVD-ILD group were found in 10 patients 
with a UIP pattern, and in 6 patients with an NSIP pat-
tern. No patients received induction chemotherapy. Path-
ological examinations of resected specimens showed that 
7 UIP pattern cases with rheumatoid arthritis (RA) were 
found in the CVD-ILD group, 18 UIP pattern cases were 
found in the IIPs group, and one NSIP pattern was found. 
The median follow-up period was 34.0 months (IQR: 
42.8 months). There was no significant difference in the 
ILD pattern on CT between the two groups. In the CVD-
ILD group, RA was the most common CVD (Table 2). Of 
those, 13 patients (81.3%) received immunosuppressive 
therapy consisting of prednisolone (PSL), methotrexate 
(MTX), tacrolimus (FK506), and mizoribine (MZ). In 
the immunosuppressant regimens, PSL (n = 8) and MTX 
(n = 2) were used as a monotherapy, and PSL with FK506 
(n = 1), PSL with MZ, and MTX with MZ were used indi-
vidually as a combination therapy.
The surgical and clinical outcomes are shown in Table 3. 
The most common operative procedure was lobectomy 
(n = 8), followed by segmentectomy (n = 5), and wedge 
resection (n = 3) in the CVD-ILD group. R0 resection was 
achieved in all patients except for one patient with patho-
logical stage IV disease in the CVD-ILD group. The rein-
forcement of the bronchial stump in major lung resection 
was performed in 4 of 8 cases (50%) in the CVD-ILD group 
and in 2 of 44 cases (4.5%) in IIPs group (p = 0.0002), and 
a pedicled intercostal muscle flap was used in all cases. 
In the CVD-ILD group, no intraoperative complications 
appeared, while postoperative complications were observed 
in 4 patients. Postoperative AE developed in 1 patient 
(6.3%), and BPF developed in 2 patients (12.5%). Patients 
with BPF underwent the reinforcement of the bronchial 
stump because of the use of immunosuppressive agents. 
The thirty- and ninety-day mortalities were 6.3%, because 
one patient died with postoperative AE (Table 3). Regard-
ing the postoperative complications, no significant differ-
ence in the incidence of postoperative AE and a signifi-
cant difference in the incidence of BPF (p = 0.0028) were 
observed between both groups. No significant differences 
in hospital stay, the incidence of postoperative complica-
tions, and 30- and 90-day mortalities were found between 
either of the groups (Table 3).
The five-year OS rates were 37.5% in the CVD-ILD 
group and 49.2% in the IIPs group (Fig. 2), and there was 
no significant deference between the two groups. A total 
10 deaths after surgery were observed in the CVD-ILD 
group during the observation period, and the causes in the 
CVD-ILD group were compared with those in the IIPs 
group (Table 4), and ILD was the second common cause 
Table 1  Comparison of the patient characteristics
*p values were calculated by Fisher’s exact test or the Chi-square test 
for categorical data, or Mann–Whitney’s U test for continuous data
**Continuous variables are expressed as the median and interquartile 
ranges which are expressed in parenthesis, and categorical variables 
are expressed as numbers and percentages (%). CVD-ILD indicates 
collagen vascular disease-associated interstitial lung disease
IIPs idiopathic interstitial pneumonias, ILD interstitial lung disease, 
CT computed tomography, UIP usual interstitial pneumonia, NSIP 
non-specific interstitial pneumonia, VC vital capacity, DLCO carbon 
monoxide diffusion capacity, KL-6 Krebs von den Lungen-6
Variables CVD-ILD group IIPs group p value*
Total number of 
patients
16 70
Age (years) 66.5 (16)** 73.0 (11.3)** 0.132
Gender 0.0201
 Male 6 (37.5%) 62 (88.6%)
 Female 10 (62.5%) 8 (11.4%)




 1 0 8 (11.4%)
 2 10 (62.5%) 31 (44.3%)
 3 6 (37.5%) 19 (27.2%)
 4≤ 0 12 (17.1%)
ILD pattern on CT 0.0709
 UIP pattern 10 (62.5%) 58 (82.9%)
 NSIP pattern 6 (37.5%) 12 (17.1%)
%VC 109.7 (40.4)** 108.7 (34.5)** 0.893
%DLco 57.4 (16.1)** 55.5 (27.6)** 0.478
KL-6 (U/mL) 481 (342.5)** 514 (440)** 0.699
Neoadjuvant chemo-
therapy
0 2 (2.9) 0.494
Pathology 0.614
 Adenocarcinoma 9 (56.3%) 30 (42.9%)
 Squamous cell carci-
noma
5 (31.2%) 30 (42.9%)
 Others 2 (12.5%) 10 (14.2%)
Pathological stage 0.153
 I 9 (56.2%) 40 (57.1%)
 II 4 (25%) 11 (15.7%)
 III 2 (12.5%) 19 (27.2%)
 IV 1 (6.3%) 0
Median follow-up 
(months)
34 (42.8)** 30.5 (35.5)** 0.89
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of death after lung cancer in both groups. This study also 
compared the OS rates between CVD-ILD with a UIP 
pattern and IPF patients, and between RA-associated 
ILD (RA-ILD) and IIPs patients (Figs.  3, 4). The five-
year OS rates were 30% in the CVD-ILD patients with 
a UIP pattern and 42.5% in the IPF patients, and no sig-
nificant difference was found between them (Fig. 3). The 
five-year OS rates were 23% in the RA-ILD patients and 
49.2% in the IIPs patients, and there was a significant dif-
ference between the two groups (p = 0.0105) (Fig. 4).
Table 2  Types of collagen 
disease and the distribution of 
ILD patterns
ILD interstitial lung disease, CT computed tomography, UIP usual interstitial pneumonia, NSIP non-spe-
cific interstitial pneumonia
Collagen Disease ILD pattern on CT The 
number of 
casesUIP pattern NSIP pattern
Rheumatoid arthritis (RA) 9 4 13
Sjögren syndrome (SjS) 1 0 1
Dermatomyositis (DM) 0 1 1
Systemic lupus erythematosus (SLE) 0 1 1
Table 3  Comparison of the 
surgical and clinical outcomes
*p values were calculated by Fisher’s exact test or the Chi-square test for categorical data, or Mann–Whit-
ney’s U test for continuous data
**Continuous variables are expressed as the median and interquartile ranges which are expressed in paren-
thesis, and the categorical variables are expressed as numbers and percentages (%)
CVD-ILD indicates collagen vascular disease-associated interstitial lung disease, IIPs idiopathic interstitial 
pneumonias, VATS video-assisted thoracoscopic surgery, AE acute exacerbation, ILD interstitial lung dis-
ease, BPF bronchopleural fistula
Variables CVD-ILD group (n = 16) IIPs group (n = 70) p value*
Operative approach 0.766
 VATS 12 (75%) 47 (67.1%)
 Thoracotomy 4 (25%) 23 (32.9%)
Operative method 0.418
 Wedge resection 3 (18.7%) 18 (25.7%)
 Segmentectomy 5 (31.3%) 8 (11.5%)
 Lobectomy 8 (50%) 40 (57.1%)
 Bilobectomy 0 3 (4.3%)
 Pneumonectomy 0 1 (1.4%)
Operative time (min) 163.5 (115.8)** 189 (117.5)** 0.682
Loss (mL) 92.5 (340.5)** 145 (281)** 0.915
Intraoperative complication 0 2 (2.9%) 0.494
Duration of drainage (days) 4 (3)** 4 (3)** 0.0777
Length of stay (days) 11 (10.5)** 12 (10)** 0.96
Postoperative complication
 Overall 4 (25%) 19 (27.1%) 0.861
 AE of ILD 1 (6.3%) 6 (8.6%) 0.759
 Prolonged air leakage 3 (18.8%) 6 (8.6%) 0.23
 Pneumonia 0 3 (4.3%) 0.399
 BPF 2 (12.5%) 0 0.0028
 Reintubation 1 (6.3%) 2 (2.9%) 0.505
 Tracheostomy 1 (6.3%) 2 (2.9%) 0.505
 Arrhythmia 1 (6.3%) 1 (1.4%) 0.248
 Others 0 4 (5.7%) 0.328
30-day mortality 1 (6.3%) 2 (2.9%) 0.505




To date, the clinical features and prognosis of CVD-ILD 
with those of IIPs are studied and reported by several inves-
tigators. Among them, Park et al. report that (1) the com-
mon types of CVD-ILD are a UIP and non-specific inter-
stitial pneumonia pattern according to the classification 
of IIPs and (2) a UIP pattern is found to more frequently 
coexist with RA than other CVD types [7]. Park et al. also 
report the (1) 3- and 5-year survival rates to be better in 
patients with a UIP pattern in the CVD group than those of 
the IIPs group, but (2) no significant difference was found 
between the patients with an NSIP pattern in both groups 
[2]. The report also suggests that IIPs may affect the prog-
nosis of lung cancer patients more strongly than CVD-
ILD. However, this study obtained the opposite results. 
Although no significant difference in the 5-year OS rates 
between CVD-ILD patients and IIPs patients was found 
(Fig. 2), the CVD-ILD group showed a lower OS rate. Fur-
ther analysis found that (1) CVD-ILD patients with a UIP 
pattern showed a lower OS rate than IPF patients (Fig. 3) 
and (2) RA-ILD patients had a significantly lower OS rate 
Fig. 2  Kaplan-Meier survival curves of collagen vascular disease-
associated interstitial lung disease (CVD-ILD) andidiopathic inter-
stitial pneumonias (IIPs) groups. The 5-year overall survival rates in 
patients with interstitiallung disease were 35.2% in CVD-ILD group 
(n = 16) (red line) and 45.1% in IIPs group (n = 70) (blue line)
Table 4  Details of the cause of death
CVD-ILD indicates collagen vascular disease-associated interstitial 
lung disease, IIPs idiopathic interstitial pneumonias, ILD interstitial 




IIPs group (n = 26) p value
0.769
Lung cancer (%) 5 (50) 16 (61.5)
ILD (%) 3 (30) 7 (27)
Postoperative AE 1 6
AE occurring ≥POD 31 2 1
Others (%) 2 (20) 3 (11.5)
Fig. 3  Kaplan-Meier survival curves of collagen vascular disease-
associated interstitial lung disease (CVD-ILD) withusual interstitial 
pneumonia (UIP) pattern and idiopathic pulmonary fibrosis (IPF) 
groups. The 5-year overallsurvival rates in patients with interstitial 
lung disease were 30% in CVD-ILD patients with UIP pattern (n 
=10) (red line) and 42.5% in IPF group (n = 58) (blue line)
Fig. 4  Kaplan-Meier survival curves of rheumatoid arthritis-associ-
ated interstitial lung disease (RA-ILD) andidiopathic interstitial pneu-
monias (IIPs) groups. The 5-year overall survival rates in patients 
with interstitiallung disease were 23% in RA-ILD (n = 10) (red line) 
and 49.2% in IIPs group (n = 70) (blue line)
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than IIPs patients (Fig.  4), indicating that IIPs failed to 
affect the prognosis of lung cancer patients more strongly 
than CVD-ILD. For explaining the lower OSs in patients 
with CVD-ILD in this study, the following reasons were 
speculated. First, the state of ILDs or CVD was ignored in 
the survival analysis, and this might have caused some bias 
in selecting the adjuvant chemotherapy and the treatment 
of recurrence of lung cancer. Second, as Sumikawa et  al. 
[8] and Sverzellati [9] reported, there could be a discrep-
ancy between the diagnosis of ILDs based on the CT and 
pathological findings. Even in this study, CVD-ILD group 
included 7 patients with a UIP pattern, and the IIPs group 
included 18 patients with a UIP pattern. Therefore, some 
patients showing a UIP pattern on CT might demonstrate 
a UIP pattern in the pathological findings. This inconsist-
ency might affect OS. Since the resected specimens did not 
always include the area of ILD, the pathological diagnoses 
of ILDs were thus considered to be difficult to confirm in 
all cases. Therefore, physicians must realize the importance 
of multidisciplinary discussions with pathologists in diag-
nosing ILDs. Another important reason to explain why the 
lower OSs were found in patients with CVD-ILD in this 
study appeared to be due to a difference in the sample size.
There are three reports regarding the 5-year survival 
rates in lung cancer patients with IIPs, and the 5-year 
survival rates in patients with NSCLC and IPF, stage IA 
NSCLC and IPF, and IPF and stage IA and IB NSCLC 
were 52% [10], 54.2% [11], and 61.6% [12], respectively. 
A multicenter retrospective study with a large numbers 
of patients with ILD who underwent lung cancer surgery 
shows that the 5-year overall survival rates are 40.0% [13]. 
As described above, even though the diagnosis of ILD 
based on the CT findings might influence the results, the 
5-year survival rates in the lung cancer patients with IIPs 
in this study showed no major difference from the reported 
results, and at least, similar to IIPs, this study showed that 
CVD-ILD might affect the long-term results of lung cancer 
surgery.
Lung resection in CVD-ILD patients could lead to post-
operative AE, which is a fatal complication. However, 
these patients may be unable to obtain as much of a benefit 
as that provided by the other treatment modalities including 
chemotherapy and radiation therapy. Kenmotsu et  al. [14] 
report that 9% of 104 NSCLC patients with ILD who are 
treated with platinum-based chemotherapy develop a chem-
otherapy-related exacerbation during the first-line chemo-
therapy. Although molecular targeting drugs, such as epi-
dermal growth factor receptor tyrosine kinase inhibitor and 
anaplastic lymphoma kinase inhibitor, have recently been 
used to treat NSCLC, these agents can cause an exacerba-
tion of ILD as an adverse effect. In addition, a dose reduc-
tion may be considered, because bone marrow suppression 
after chemotherapy in CVD-ILD patients who received 
immunosuppressive agents can lead to the development 
of severe infectious diseases. Ozawa et al. [15] report that 
pre-existing interstitial disease is a predictive factor of 
extensive radiation pneumonia. From these results, chemo-
therapy and radiation therapy for lung cancer with CVD-
ILD are therefore not considered to be a more effective 
treatment modality than surgery. Therefore, this study con-
sidered that lung cancer patients with CVD-ILD would be 
candidates for surgical treatment.
The prediction and prevention of postoperative AE is 
quite important. Several reports suggest that the following 
items could be predictors of postoperative AE; patient age, 
the duration of postoperative drainage and intraoperative 
fluid balance [16–18], typical honeycombing and possible 
honeycombing patterns on the chest CT findings [19], and 
the I/M ratio, which is the ratio of the peak standardized 
uptake value (SUV) of the interstitial lung disease area to 
the mean SUV of the mediastinum [20]. Although medi-
cations are used to prevent postoperative AE of ILD [5, 
21], no evidence for prophylaxis has yet been established. 
Ulinastatin, as a prophylactic agent used in this study for 
postoperative AE, showed the incidence rates of postopera-
tive AE in this study to be 6.3% in the CVD-ILD group and 
2.9% in the IIP group, and these results were more favora-
ble than the 9.3% rate reported in a multicenter study in 
Japan reported by Sato et  al. [22]. Recently, the effect of 
perioperative pirfenidone treatment for preventing postop-
erative AE of ILD has been reported [23–25], further inves-
tigations are expected. Hozumi et  al. [26] investigate the 
risk factor of AE of ILD in RA patients, and a univariate 
analysis revealed that an older age at the time of intersti-
tial pneumonia diagnosis, the UIP pattern on HRCT, and 
MTX usage are associated with AE of ILD. This study was 
unable to identify any predictors of AE of ILD in patients 
with CVD-ILD, because postoperative AE appeared in only 
one patient with CVD-ILD. However, Sato et al. [22] report 
that preoperative steroid use is an independent risk factor of 
postoperative AE, and in this study, the use of immunosup-
pressive agents in CVD-ILD patients might be a risk factor 
of postoperative AE. Describing the severity of postopera-
tive AE of ILD is also important, but it is difficult because 
there is no report about grading postoperative AE. Katay-
ama et al. reported on the Japan Clinical Oncology Group 
postoperative complications criteria, including six thoracic 
complications [27]. Postoperative AE is not included in 
these criteria, however, grading postoperative AE may be 
a useful tool when thoracic surgeons make an investigation 
concerning postoperative AE. Future considerations should 
thus be expected.
Besides being an essential for treating CVD, immu-
nosuppressive agents can cause some problems in the 
perioperative and long-term periods for CVD patients 
undergoing lung resection. First, infectious complications 
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such as pneumonia caused by immunosuppression, pro-
longed air leakage, and BPF due to the inhibition of 
wound healing could be induced by immunosuppressive 
agents. Prolonged air leakage can cause an infection in 
the intrapleural space, leading to pyothorax. The tempo-
rary discontinuation of immunosuppressive agents could 
be acceptable as long as the state of CVDs is stable, and 
consultations with rheumatologists are therefore impor-
tant before surgery. In this study, the CVD-ILD group 
showed a higher incidence of BPF than the IIPs group 
in spite of the reinforcement of the bronchial stump, this 
higher incident rate would be a risk factor for inducing 
serious problems, because BPF can lead to fatal pyo-
thorax and broncho-pulmonary artery fistula (BPAF). 
Pyothorax developed in CVD-ILD patients treated 
with immunosuppressive agents and it was expected to 
become exacerbated. Although bronchial closure meth-
ods and a predictive score for BPF have been reported 
[28, 29], no evidence showing the effectiveness of the 
reinforcement of the bronchial stump to prevent BPF is 
available. In fact, two patients who developed BPF in the 
CVD-ILD group were applied with the reinforcement 
of the bronchial stump. In the authors’ department, this 
procedure was routinely performed for high-risk patients 
including patients suffering from severe diabetes melli-
tus, took immunosuppressive agents, or received neoad-
juvant chemoradiation therapy, because it was considered 
possible to avoid fatal BPAF by isolating the bronchial 
stump and pulmonary artery. Second, calcineurin inhibi-
tors, such as tacrolimus could worsen the prognosis of 
cancer over the long term, because these agents induce 
tumor growth, invasion, and metastasis [30]. In this study, 
because only one patient took tacrolimus, a calcineurin 
inhibitor, this study was unable to obtain any conclusive 
results regarding these inhibitors, because the number of 
observations was insufficient. Therefore, future investi-
gations are called to clarify their effect. Third, the doses 
of immunosuppressive agents can be increased upon the 
exacerbation of the CVD status, and bone marrow sup-
pression due to chemotherapy may lead to a critical infec-
tion. Therefore, a decrease in the dose of chemotherapy 
results in an insufficient curative effect, thereby affecting 
the prognosis.
Because this study was a retrospective single institu-
tional study, the number of cases investigated might be 
insufficient, and the small sample size could be a limita-
tion associated with this study. The results of this study 
should be confirmed in a multicenter clinical study 
with a larger number of patients. The diagnosis of ILD 
in this study was based on the CT findings, because the 
resected specimens did not always include the area of 
ILD. There were a variety of CVD types and immuno-
suppressive treatment regimens in this study, and further 
investigations with a sufficient number of cases are called 
in the future.
Conclusion
In conclusion, this study speculated that the incidence rate 
of postoperative AE of ILD and mortality in CVD-ILD 
patients after lung cancer surgery were not higher than 
those of IIPs patients. CVD-ILD patients might thus have 
poor prognosis after lung resection for NSCLC similar to 
that seen in IIPs patients.
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